Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy
- DOI
- 10.1016/j.ymthe.2020.11.019
- Published
- 2021-03
- Container
- Molecular Therapy
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.ymthe.2020.11.019,
title = {Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy},
author = {Pierre Dillard and Hakan Köksal and Solrun Melkorka Maggadottir and Anna Winge-Main and Sylvie Pollmann and Mathilde Menard and Marit Renée Myhre and Gunhild M. Mælandsmo and Vivi Ann Flørenes and Gustav Gaudernack and Gunnar Kvalheim and Sébastien Wälchli and Else Marit Inderberg},
year = {2021},
journal = {Molecular Therapy},
doi = {10.1016/j.ymthe.2020.11.019},
url = {https://doi.org/10.1016/j.ymthe.2020.11.019}
}RIS
TY - JOUR TI - Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy AU - Pierre Dillard AU - Hakan Köksal AU - Solrun Melkorka Maggadottir AU - Anna Winge-Main AU - Sylvie Pollmann AU - Mathilde Menard AU - Marit Renée Myhre AU - Gunhild M. Mælandsmo AU - Vivi Ann Flørenes AU - Gustav Gaudernack AU - Gunnar Kvalheim AU - Sébastien Wälchli AU - Else Marit Inderberg PY - 2021 JO - Molecular Therapy DO - 10.1016/j.ymthe.2020.11.019 UR - https://doi.org/10.1016/j.ymthe.2020.11.019 ER -
APA
Dillard, P., Köksal, H., Maggadottir, S. M., Winge-Main, A., Pollmann, S., Menard, M., Myhre, M. R., Mælandsmo, G. M., Flørenes, V. A., Gaudernack, G., Kvalheim, G., Wälchli, S., & Inderberg, E. M. (2021). Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2020.11.019
Source records
- crossref · retrieved 2026-09-26T11:28:24.524Z